Glenmark Pharmaceuticals gets USFDA’s final nod for Progesterone Vaginal Inserts
Glenmark’s Progesterone Vaginal Inserts, 100 mg will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals has received final approval from the United States Food & Drug Administration (U.S. FDA) for Progesterone Vaginal Inserts, 100 mg, determined by the FDA to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Endometrin Vaginal Inserts, 100 mg of Ferring Pharmaceuticals Inc. Glenmark’s Progesterone Vaginal Inserts, 100 mg will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.
According to IQVIA sales data for the 12-month period ending February 2026, the Endometrin Vaginal Inserts, 100 mg market achieved annual sales of approximately $59.2 million.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
